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REVIEW
Tyrosine and tryptophan hydroxylases as therapeutic targets in human disease
Kai Waløena, Rune Kleppeb, Aurora Martineza and Jan Haavika
aDepartment of Biomedicine and K.G. Jebsen Centre for Neuropsychiatric Disorders, University of Bergen, Bergen, Norway; bComputational Biology
Unit, Department of Informatics, University of Bergen, Bergen, Norway
ABSTRACT
Introduction: The ancient and ubiquitous monoamine signalling molecules serotonin, dopamine,
norepinephrine, and epinephrine are involved in multiple physiological functions. The aromatic
amino acid hydroxylases tyrosine hydroxylase (TH), tryptophan hydroxylase 1 (TPH1), and tryptophan
hydroxylase 2 (TPH2) catalyse the rate-limiting steps in the biosynthesis of these monoamines. Genetic
variants of TH, TPH1, and TPH2 genes are associated with neuropsychiatric disorders. The interest in
these enzymes as therapeutic targets is increasing as new roles of these monoamines have been
discovered, not only in brain function and disease, but also in development, cardiovascular function,
energy and bone homeostasis, gastrointestinal motility, hemostasis, and liver function.
Areas covered: Physiological roles of TH, TPH1, and TPH2. Enzyme structures, catalytic and regulatory
mechanisms, animal models, and associated diseases. Interactions with inhibitors, pharmacological
chaperones, and regulatory proteins relevant for drug development.
Expert opinion: Established inhibitors of these enzymes mainly target their amino acid substrate
binding site, while tetrahydrobiopterin analogues, iron chelators, and allosteric ligands are less studied.
New insights into monoamine biology and 3D-structural information and new computational/experi-
mental tools have triggered the development of a new generation of more selective inhibitors and
pharmacological chaperones. The enzyme complexes with their regulatory 14–3–3 proteins are also
emerging as therapeutic targets.
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All animals are dependent on catecholamine and serotonin
signaling for many physiological functions, ranging from
embryonic growth and development to neurotransmission,
blood clotting and endocrine, kidney, and cardiovascular
functions [1,2]. For many years, the enzymes, transporters,
and receptors involved in the metabolism and signaling of
these monoamine neurotransmitters and hormones have
been primary therapeutic targets for many human diseases
within neurology, cardiology, and psychiatry [3]. As new
roles of monoamine signaling have been discovered in
regulation of endocrine signaling, hemostasis, gastrointest-
inal function, weight, and bone homeostasis and liver func-
tion, the interest in pharmacological modification of these
signaling pathways has increased [4]. Due to peripheral
monoamines being unable to cross the blood–brain barrier,
the central and peripheral serotonin and catecholamine
systems can be separately targeted by different pharmaco-
logical agents [4].
New insights into the structure, regulation, and diverse
roles of the aromatic amino acid hydroxylases (AAAHs): tyro-
sine hydroxylase (TH), tryptophan hydroxylase 1 (TPH1), and
tryptophan hydroxylase 2 (TPH2) that synthesize these mono-
amines (Figure 1) have triggered a new interest in these
enzymes as therapeutic targets.
2. AAAHs and human disease
TH, TPH1, and TPH2 belong to the AAAH family of enzymes
that catalyze the hydroxylation of their respective aromatic
amino acids in the presence of molecular oxygen, tetrahydro-
biopterin (BH4), and iron [5,6]. In addition to TH, TPH1, and
TPH2, phenylalanine hydroxylase (PAH) is also a member of
this family and is responsible for the catalytic conversion of
phenylalanine into tyrosine [5,7]. All the AAAHs occupy key
regulatory positions in their metabolic pathways (Figure 1)
[7–10].
Until recently, the interest in these enzymes has mainly
been related to the roles of monoamines as neurotransmitters
in the central nervous system (CNS) where they are involved in
regulation of cognitive and motor functions, as regulators in
the peripheral autonomic nervous system as well as ‘stress
hormones’ [1,11,12]. Moreover, altered monoamine functions,
triggered by dysfunction of the AAAHs, are associated with
neurometabolic and neuropsychiatric disorders [1]. An exam-
ple of this is phenylketonuria (PKU) which is associated with
mutations in PAH and is characterized by the accumulation of
phenylalanine and its degradation products. Untreated phe-
nylketonuria has detrimental effects on brain development
and function [13]. Different treatment strategies to target
PAH deficiency and malfunction have recently been reviewed
and will not be further discussed here [13,14].
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TH is the enzyme responsible for the rate limiting, catalytic
conversion of tyrosine into L-DOPA, a precursor of dopamine,
norepinephrine, and epinephrine [10] (Figure 1). At least four
isoforms of human TH are generated by alternative splicing of
a single gene: that is, TH1-4 [15]. TH is mainly expressed in the
noradrenergic and dopaminergic neurons of the brain, chro-
maffin cells of the adrenal medulla, and sympathetic neurons
[8,16]. In mice, and probably also humans, complete knockout
of TH activity leads to cardiac failure [11,17]. This effect seems
to be normalized by quite low residual TH activity, as also
found in human patients with TH deficiency, where the major
phenotype is motor dysfunction [1,18]. This is consistent with
the important function of dopamine in the basal ganglia,
which is necessary for the release of inhibition by the major
GABAergic pathways that originate in the striatum [1,18]. In
addition to their roles in motor systems, in the CNS, dopamine
and norepinephrine are important neuromodulators involved
in multiple functions, such as attention, working memory,
learning, addiction, motivation, and emotions [1,12].
2.2. TPH1 and TPH2
The TPHs are responsible for the catalytic conversion of L-
tryptophan into 5-hydroxy-L-tryptophan which is a precursor
of serotonin and melatonin (Figure 1) [4]. Serotonin is a neu-
rotransmitter and a hormone in several physiological func-
tions, such as sleep, pain, appetite, sexual behavior, and
mood [1,2,4]. Melatonin is associated with consolidation of
sleep and other functions [19]. Human TPH1 and TPH2 are
encoded by two different genes located on chromosomes 11
and 12, respectively, and the two human TPH proteins have an
overall sequence identity of 71% [20]. Although they have
identical catalytic mechanisms and similar substrate specifici-
ties, they have different phosphorylation sites, different pat-
terns of expression, and are involved in distinct physiological
processes [20]. TPH1 is mainly expressed in the enterochro-
maffin cells of gastrointestinal tract, but also in adrenal glands,
kidney, and the pineal gland, where melatonin is synthesized.
Most of the circulating serotonin is derived from TPH1 but is
transported into platelets where it is stored in dense granules.
In contrast, TPH2 is found in serotonergic neurons originating
Article highlights
● Catecholamines and serotonin have multiple physiological functions.
Altered functions of these monoamines have been implicated in
many different disease states. The AAAHs: TH, TPH1, and TPH2 are
key enzymes in the biosynthesis of these molecules. Here we describe
how new insights into the structure, regulation and biological func-
tions of TH, TPH1, and TPH2 have generated new interest in these
enzymes as therapeutic targets.
● The monoamine signalling pathways and the involvement of TH,
TPH1, and TPH2 are reviewed, as well as their protein structures
and catalytic mechanisms.
● Various regulatory mechanisms of these AAAH’s are presented,
including feedback inhibition, phosphorylation, and regulation by
14-3-3 proteins.
● The structure, binding mechanism, and involvement of 14-3-3 pro-
teins with AAAHs are described.
● Diseases associated with TH, TPH1, and TPH2 and animal models of
disease are discussed, as well as past and current therapeutic
approaches targeting these enzymes.
● Novel therapeutic approaches to treat AAAH associated disorders are
suggested, including pharmacological chaperones targeting the
mutant enzymes and compounds that can modulate their protein-
protein interactions, notably with 14-3-3 proteins.
This box summarizes key points contained in the article.
Figure 1. Reaction pathway of the catecholamine synthesis (left) and serotonin and melatonin synthesis (right) pathways. In the catecholamine synthesis, L-tyrosine
is converted to L-DOPA by tyrosine hydroxylase in the presence of BH4, O2, and Fe
2+. L-DOPA is further converted into dopamine by aromatic L-amino acid
decarboxylase. Dopamine is converted to norepinephrine by dopamine β-hydroxylase. Finally, norephinephrine is converted to epinephrine by phenylethanolamine
N-methyltransferase. In the serotonin and melatonin synthesis pathway, L-tryptophan is converted to 5-hydroxyl-L-tryptophan by tryptophan hydroxylase in the
presence of BH4, O2, and Fe
2+. 5-hydroxyl-tryptophan is converted to serotonin by aromatic L-amino acid decarboxylase. Following this, serotonin is converted to
N-acetylserotonin by serotonin N-acetyltransferase. Finally, N-acetylserotonin is converted to melatonin by hydroxyindole-O-methyltransferase. In both pathways,
BH4 is converted to q-BH4 in the process of the reaction.






































from the raphe nuclei in the brain with widespread projections
to many cortical areas [4].
2.3. AAAH structure and catalysis
The AAAHs are tetrameric enzymes of identical subunits, but
PAH can also be dimeric [5,21]. All four enzymes present a 3-
domain organization including N-terminal regulatory, catalytic,
and C-terminal oligomerization domains (Figure 2) [22]. The
AAAHs display high-sequence identity. The 293-residue long
catalytic domains, which are largely α-helical, exhibit approxi-
mately 65% sequence identity across the four human
enzymes. Several partial AAAH structures, mainly of the cata-
lytic domains, have been published or deposited in the
Protein Data Bank (Figure 2). In addition, the crystal structure
of full-length rat PAH (PDB: 5DEN) [23], as well as the solution
structures of the regulatory domain (PDB: 2MDA) [24], and full-
length TH has recently been published [25]. As expected from
the high-sequence identity, the superimposition of human
AAAH structures also shows high 3D structural homology,
notably for the catalytic domains (Figure 3(a)) [22,26]. The
geometric arrangement of the domains may vary. The struc-
ture of full-length tetrameric PAH shows that the ACT regula-
tory domains are separated from each other (Figure 3(b)) and
probably dimerize upon activation of the enzyme by L-Phe
[23]. In contrast, the regulatory domains of TH dimerize also in
the resting state, in the absence of substrate, as observed both
by NMR [24] and SAXS [25]. Another peculiarity of TH is its 43-
residue unstructured N-terminal that imposes an elongated
conformation to TH and has an important regulatory role,
hosting the phosphorylation sites and interacting with binding
partners [25,27].
The AAAHs hydroxylate their respective amino acid sub-
strates, using nonheme Fe2+ and tetrahydrobiopterin (BH4) as
cofactors and dioxygen as additional substrate (Figure 1). A
highly reactive Fe4+=O hydroxylating intermediate – formed
by the active site iron, oxygen, and BH4 – catalyzes the hydro-
xylation of the substrate [7]. In the reaction, molecular oxygen
is catalytically cleaved and each of the oxygen atoms is incor-
porated into BH4 and the aromatic ring of the substrate. The
hydroxylated cofactor (BH4–4a-carbinolamine) is regenerated
back to BH4 by the consecutive action of pterin 4a-carbinola-
mine dehydratase and dihydropteridine reductase [5,7].
For PAH, crystal structures are available for the enzyme
with bound BH4 and substrate analogs (norleucine and thie-
nylalanine), and the active site of PAH, as a representative of
the AAAH’s active sites, is shown in Figure 4. The catalytic iron
binds to conserved His290, His285, and Glu330 (numeration in
Figure 2. Schematic representation of the AAAH domains, regulatory (purple), catalytic (red) and oligomerization (blue) domains. The relative sizes of the known
crystal structures are indicated as well as the PDB code. The AAAH proteins are labelled with the species (r: rat; h: human). The presented structures were selected
based on top hits of BLAST runs with the PDB database. The query sequence was the sequence of the Homo sapiens AAAH available on Uniprot. Full color available
online.






































human PAH), which form a 2-His-1-carboxylate facial triad. The
cofactor binds close to the iron through conserved interac-
tions within the AAAHs, that is, π-stacking with Phe254 and
electrostatic/hydrogen bonding with Glu286 (Figure 4) [26].
The dihydroxypropyl side chain at C6 of BH4 also establishes
specific hydrogen bonding interactions with non-conserved
residues, which determine the specific configuration of this
side chain for BH4 bound to each AAAH. These differences
have been discussed in the context of hydroxylase-specific
cofactor analogs and inhibitors [26]. X-ray crystallography
has also provided the structure of TPH1 complexed with the
cofactor (PDB: 1MLW) [28] natural substrate L-Trp (PDB: 3E2T)
[29], which is in agreement with the binding of substrate
analogs to PAH (Figure 4). The amino acid substrate binds
opposite to the cofactor, at the other side of the iron, inter-
acting with conserved Arg270 and His285 (in PAH), whereas
Val379/Asp425/Ile366 and Trp326/Trp372/Phe313 (numeration
in human PAH/TH/TPH1) contribute to the specificity of the
AAAHs for their corresponding amino acid substrates [26].
2.4. Regulation of TH and TPH
As the biosynthetic pathways for dopamine and serotonin share
several of the same pathway components (Figure 1), including
the vesicular monoamine transporter, similar mechanisms for
regulation could be expected. One major homeostatic or adap-
tive regulation of these monoamines is by controlling the
cellular or even subcellular activity of TH and the TPHs. This
makes the hydroxylases attractive targets for modulating
monoamine levels and function. There are, however, some
notable differences, such as end product feedback inhibition
for homeostatic regulation of catecholamines and serotonin.
Whereas TH is feedback inhibited and stabilized by catechola-
mines binding to the active site, serotonin lacks the catechol
structure with the two adjacent hydroxyl groups that coordi-
nate to the active site iron atoms and does not display such
inhibition [5,30–32]. On the other hand, all AAAHs are inhibited
by catechol binding [5,26,32], although the physiological rele-
vance for the inhibition of PAH and the TPHs is unclear.
Figure 4. Crystal structure of PAH (PDB: 1MMK) cocrystalized with tetrahydrobiopterin (BH4) and substrate analogue thienylalanine. The active site is magnified to
show the Fe2+ which interacts with His285, His290, and Glu330. The substrate analogue binds at the amino acid substrate binding site of the AAAHs.
Figure 3. The domain organization and the tetrameric structure of the AAAHs. a) Superimposition of one subunit of each of the AAAHs, PAH, TH, TPH1, and TPH2.
Blue: PAH (PDB: 5DEN), red: TH (PDB: 2XSN), green: TPH1 (PDB: 1MLW) and magenta: TPH2 (PDB: 4V06). The domains are highlighted and labelled. b) Tetrameric
form of PAH (PDB: 5DEN). Each monomer of the tetrameric complex is represented in different colours. Full color available online.






































In the CNS, homeostatic regulation by cellular autorecep-
tors is found at dopaminergic, noradrenergic, and serotonergic
neurons. The autoreceptors not only lower the excitation and
secretion from these cells, but also target the hydroxylases by
altering signal-mediated phosphorylation of the enzymes,
leading to lowered cellular activity [33]. In addition to the
cAMP/protein kinase A (PKA)-signaling pathway that is modu-
lated by autoreceptors [33], several other pathways are found
to regulate the phosphorylation status and activities of these
enzymes. Thus, multiple phosphorylation sites are described,
most of them residing in the N-terminal regulatory
domain [5,32].
2.4.1. Regulation of TH by phosphorylation
Mammalian TH has four phosphorylation sites in its regula-
tory domain, corresponding to Ser8/Thr8, Ser19, Ser31, and
Ser40 in the murine/bovine or human TH1 sequences.
Phosphorylation of Ser40 is best understood, as it directly
activates TH by reversing binding of catecholamine inhibi-
tors and by increasing the affinity for BH4 [30,34]. Ser40 is
targeted by cyclic nucleotide-activated kinases, as well as
kinases downstream of MAPK1/2 such as MAPK-activated
protein kinase 1 (MAPKAP-K1 or p90 Ribosomal S6 Kinase)
and mitogen- and stress-activated kinase 1 (MSK1) that is
also activated by p38 MAPKs [35,36]. The MAPK1/2 on the
other hand phosphorylates TH primarily at Ser31, a site that
is also targeted by cyclin-dependent kinase 5, and phos-
phorylation of this site is shown to activate TH about two-
fold in situ [37]. On the other hand, phosphorylation of
Ser19 on TH does not directly alter its activity but allows
for binding of the regulatory 14-3-3 proteins that can lead to
an activation and stabilization of TH [38,39]. Major kinases
that target Ser19 are the Ca2+/calmodulin-dependent pro-
tein kinase II (CaM-KII) and the stress-activated kinase MAPK-
activated protein kinase 2 (MAPKAP-K2) downstream of p38
MAPK [36,40]. The Ser40 site of TH seems to be under strict
control in catecholamine producing cells and tissues, with a
general low phosphorylation stoichiometry (3–5%/subunit),
whereas the phosphorylation levels of Ser19 and Ser31 are
higher (about 10–30%/subunit) [41].
2.4.2. Regulation of TPH by phosphorylation
The Ser19 site of TPH2, which is lacking in TPH1, is homolo-
gous to the Ser19-TH site and is phosphorylated by both CaM-
KII and PKA [20,42]. PKA additionally phosphorylates TPH2 at
Ser104, but the modest activation seems to arise from the
Ser19 site, as does the association with 14-3-3 proteins [43].
Binding of 14-3-3 proteins further activates TPH2 and stabilizes
the enzyme [44]. In addition, the bound 14-3-3 inhibits depho-
sphorylation of TPH2 and thereby prolongs the activation
signal. Although TPH1 lacks the Ser19 site, it still binds to
14-3-3 proteins in response to phosphorylation by PKA and
CaM-KII through its Ser58 site [45,46]. More potent activation
by 14-3-3 is reported for TPHs purified from native sources
than for TPHs expressed in bacteria [44].
2.4.3. 14-3-3 proteins
The 14-3-3 proteins are a highly conserved family of acidic
proteins encoded by multiple genes in all eukaryotic species,
including plants and mammals (13 genes in Arabidopsis and 7
in mammals, respectively) [47]. Binding assays have revealed
more than 100 cellular binding partners, although the physio-
logical role of the interaction is known only for a minority of
these proteins. Remarkably, out of all these binding partners,
TH and TPH were the first proteins to be identified to interact
with 14-3-3 [48].
14-3-3 binding is in most cases dependent on Ser/Thr
phosphorylation of the target protein. The most common
binding site is a serine residue flanked by an arginine and
proline residue [47,49]. There are three binding motifs of 14-3-
3, called ‘modes I–III’: mode I: RSXpSXP, mode II: RXY/FXpSXP,
and mode III: pS/pT X1–2–CO2H (X is not Pro) [47]. These
binding modes are considered to be optimal, but due to the
large number of binding partners, this is not absolute [49].
Binding of 14-3-3 can structurally alter its binding partner or
its interaction with other molecules, which can give rise to a
number of different regulatory effects. These properties, along
with the many binding partners, have placed 14-3-3 proteins
as important players in cell cycle and signal regulation, meta-
bolism and cytoskeletal control, trafficking, apoptosis, and
gene transcription [47,49].
In mammals, there are seven isoforms of 14-3-3: beta,
gamma, epsilon, sigma, zeta, eta, and tau. The sequence iden-
tity between the seven isoforms is around 46%. Comparison
between structures available on PDB also shows a high struc-
tural similarity [49]. As 14-3-3 is involved in such essential
cellular pathways, 14-3-3 is found in various tissue types
throughout the body. Different isoforms of 14-3-3 are
expressed at different levels between tissue types, but all iso-
forms are highly expressed in brain [47,49].
14-3-3 proteins form dimers and depending on the isoform
can form homo- or heterodimers. A single 14-3-3 monomer is
made up of nine antiparallel α-helices (Figure 5). A single
monomer has a large, ‘C’ shaped, amphipathic, ligand binding
groove which is formed by H3, H5, H7, and H9 α-helices. The
14-3-3 dimer forms a ‘W’ shape with each of the ligand bind-
ings grooves making up the inner surface of the dimer. The
dimerization interface of a dimer is between H1 and H2 of one
monomer and H3 and H4 of the other. The dimerized 14-3-3
reveals a large possibility of flexibility between the individual
subunits, which probably contributes to the promiscuous
binding capacity of 14-3-3s. Despite this flexibility, 14-3-3
maintains its shape in the apo form and possibly acts as a
‘molecular anvil,’ forming a rigid scaffold when binding to a
ligand protein [49].
2.4.4. Structural considerations of the 14-3-3–TH complex
Currently, there are many structures available for the mamma-
lian 14-3-3 isoforms, both as apo proteins and in complex with
ligand proteins and peptides [47,49]. Thus far, the crystal
structure of TH and TPHs including their N-terminal domain
has not yet been solved. This limits our understanding of the
hydroxylase-14-3-3 protein complex formation, which requires
phosphorylation of Ser19 in both TH and TPH2 for binding to
14-3-3 [27,43]. However, the crystal structure of the Ser19
phosphorylated N-terminal peptide region of TH (pNT; resi-
dues 1–43) bound to 14-3-3 has been solved (PDB: 4J6S). Here,
the pNT region adopts an extended conformation that binds






































to the phosphopeptide binding ‘triad’ involving two arginines
and one tyrosine within the main amphipathic groove
(Figure 5). The complex structure reveals that pNT-TH binds
to 14-3-3 in a similar fashion as to other known peptides e.g.
1QJA, 1A38, 1A37, 2B05 [50,51]. As TPH has a high-sequence
identity with TH and binds to 14-3-3 via a similarly phosphory-
lated serine, this 14-3-3–pNT-TH complex may be used as a
model for the 14-3-3–TPH complex [43] (Figure 5).
Although Ser19 phosphorylation of TH is a determinant for
complex formation with 14-3-3, the interactions involved in
full length TH are probably more extensive than for pNT-TH.
Thus, the affinity constant measured between 14-3-3γ and
Ser19 phosphorylated TH is two orders of magnitude higher
that the affinity measured for the pNT-TH [27,52]. As different
mammalian 14-3-3 dimers have similar affinity toward Ser19
phosphorylated TH, the interaction surfaces may mainly be
comprised of conserved surface regions on 14-3-3, close to
the binding groove [38,49]. As found in the complexes of 14-3-
3 with PMA2H+-ATPase (PDB: 2O98) and 14-3-3 with serotonin
N-acetyltransferase (AANAT) (PDB: 1IB1), both proteins have a
flexible loop which binds to the phosphopeptide binding triad
of 14-3-3 [53,54]. The maximal stoichiometry of the TH:14-3-3
complex was found to be two 14-3-3 dimers for one TH
tetramer [52]. Although TH with low phosphorylation stoichio-
metry (0.15 phosphate/subunit) at Ser19 showed very similar
binding kinetics to 14-3-3 as that of fully phosphorylated TH,
further experimental evidence is needed to conclude on the
possible binding of one or two phospho-Ser19 residues to the
same 14-3-3 dimer [52]. Furthermore, this result also points to
the importance of other TH regions than phospho-Ser19
determining the binding affinity, justifying efforts to solve
the structure of the TH:14-3-3 complex with the major brain
isoforms.
3. Diseases associated to mutations and dysfunction
of the AAAH
Most of the drugs targeting monoamine signaling, including
some inhibitors of AAAHs that are marketed today, are based
on serendipitous discoveries made 50–100 years ago. This was
before the advent of modern structural biology, the omics
revolution, high-throughput screening, and computational
methods. Recently, it has been shown that with the use of
modern drug discovery methods, it is possible to develop
novel and innovative drugs that target AAAHs.
As shown in Table 1, many different human symptoms or
diseases have been attributed to decreased or elevated levels
of catecholamines or serotonin. With the exception of the
Mendelian forms of DOPA responsive dystonia and/or infantile
parkinsonism, all these diseases are complex conditions with a
pathophysiology involving many genetic and environmental
factors. Still, promising results have been obtained by drugs
that modulate AAAH functions and indirectly alter monoamine
levels.
3.1. TH in human physiology, diseases, and mouse
models of THD
Tyrosine hydroxylase deficiency (THD; OMIM *191290) pro-
duces a varied clinical picture, mainly as a DOPA-responsive
dystonia and/or infantile parkinsonism [1]. This rare autosomal
recessive neurometabolic disorder is caused by mutations in
the TH gene, largely missense mutations, but a few variants in
the promoter region have also been reported. THD is diag-
nosed in infancy with symptoms ranging from mild
Parkinson’s disease-like symptoms to severe encephalopathy.
Based on clinical and biochemical features, THD can be
Figure 5. The dimeric structure of 14–3-3γ in complex with the Ser19 phosphorylated N-terminal region of TH peptide (pNT-TH; 1–43 residues) (PDB: 4J6S). The
14–3-3γ monomers are represented as blue and cyan. The pNT-TH peptides are coloured magenta and green. The box on the right presents the binding mode of
pNT-TH with 14–3-3γ Phosphorylated Ser19 interacts with Arg57, Arg132, and Tyr133 (14–3-3γ numericals), and these residues are represented in blue. pNT-TH is
represented in green. Full color available online.






































broadly classified into type A and type B. Type A THD is a
progressive hypokinetic-rigid syndrome with dystonia with
symptoms often appearing within the first year of life. Type
B THD is a complex encephalopathy with onset within the first
3 months of life [18]. To date, data from approximately 70
patients have been recorded (according to www.biopku.org/
pnddb) and certain genotype–phenotype correlations have
been proven [77]. The most recurrent mutation in the TH
gene (ca. 30% of all mutant alleles) is p.R233H (p.R202H in
the TH1 isoform), largely associated with type B THD, showing
a substantial reduction of dopamine levels and often a bad
response to L-DOPA treatment [18]. Whereas the lack of viabi-
lity of Th-knockout mice was established early [11,17], it is still
unclear what is the threshold activity of TH needed for suffi-
cient striatal dopamine levels, and how this relates to mis-
sense mutations affecting TH stability versus TH activity.
Recent development of THD models using knock-in technol-
ogy has shown the loss of function due to protein misfolding
and instability. Thus, the Th-knock-in mouse with the mutation
p.R203H, equivalent to the human TH-p.R233H (TH1-p.R202H),
showed normal survival but gradual loss of total brain TH-
immunoreactivity and central catecholamines that is not
caused by loss of dopaminergic neurones. Whereas the sub-
stantia nigra presented almost normal levels of TH, the
enzyme was distinctly absent in the striatum [78]. Both the
loss of TH and its mislocalization in the nigrostriatal pathway
were explained by the conformational instability of the
mutant, further aggravated by a deficient stabilization by
catecholamines that would result in defective transport to
striatal axonal terminals. The p.R203H mice suffered from
hypotension, hypokinesia, reduced motor coordination, wide-
based gate, and catalepsy, with a marked diurnal fluctuation
of the motor defects. All together these symptoms, which did
not improve with standard L-DOPA treatment, point to this
mouse as a suitable clinical model of Type B THD.
The Th-knock-in mouse with the mutation p.Q382K, equiva-
lent to the human TH-p.Q412K (TH1-p.Q381Q), has also been
characterized, rather showing a recapitulation of the core
features of Type A THD, with a dystonia that is L-DOPA
responsive [79]. In addition to the kinetic defect of the muta-
tion [80], a conformational destabilization and misfolding was
also noted [77] and associated to a marked decrease of TH in
brain regions containing axonal terminals [79]. These authors
also characterized defects in the microstructure of striatal
synapses and found specific abnormal receptor responses in
the p.Q382K mouse. Furthermore, the diurnal fluctuation in
the dystonia was so striking that these mutant mice showed
normal motor performance right after the sleep period [78,79].
Although THD is not accompanied by neurodegeneration, it
shares several traits with Parkinson’s disease, where degenera-
tion of dopaminergic neurons in the midbrain results in loss of
striatal dopamine and the characteristic motor phenotype [81].
Multiple sources of evidence indicate that other neuropsy-
chiatric disorders, such as schizophrenia, depression, bipolar
disorder, autism, and ADHD, either directly or indirectly, are
associated with altered monoamine functions, notably dopa-
mine [1]. Most of the current medications for these conditions
either increase or decrease the effective levels of dopamine,
norepinephrine, and epinephrine in monoaminergic synapses.
For example, the dopamine and norepinephrine transporter
blockers methylphenidate, amphetamine, and atomoxetine
are used to treat ADHD symptoms [82], whereas as L-DOPA-
responsive dystonia, Parkinson’s disease is mainly treated by
supplying L-DOPA, the product of TH [18,60] (Figure 1). An
alternative treatment aiming to stimulate dopamine synthesis
in such conditions could be stimulation or stabilization of the
TH enzyme. As discussed below, such treatment options might
include pharmacological chaperones (PCs) or small molecule
modulation of protein–protein interactions (PPIs). The pre-
sently available THD mice models not only represent robust
models of the human patients that carry the corresponding
mutations and contribute to our understanding of pathophy-
siological mechanisms of THD, but are also valuable for the
development of these alternative therapeutic approaches.
Furthermore, they seem suitable for the study of treatment
strategies based on circadian regulation of TH activity and/or
restorative properties of sleep, which have so far been the
subject of little research.
Table 1. Examples of human conditions that may be targeted by inhibitors or stimulators of TH or TPH activities.
Inhibition Compound(s) Stimulation Compound(s)










Alpha-methyl-tyrosine [59] Parkinson’s disease L-DOPA supplementation [60]
Depression Tyrosine [61]







Irritable bowel syndrome LX-1031 [67,68]
LP-615819 [69]
Obesity LP533401 [70]






TPH2 Anxiety [76] Depression Tryptophan [61], BH4
This list includes past and present treatment possibilities. Along with the examples of human conditions that may be targeted, potential
pharmacological treatment options that have been proposed are also presented.






































3.2. Synthetic TH inhibitors and substrates
Rapidly following the discovery of TH as the rate-limiting
enzyme in catecholamine synthesis, a range of different nat-
ural and synthetic compounds was tested as alternative sub-
strates and inhibitors of this enzyme (reviewed in Refs. [5,6]).
Although many of the substances were shown to reduce
catecholamine production in experimental systems, few com-
pounds have been subject to detailed mechanistic studies or
clinical trials [5,6,55,59]. In particular, the substrate analogs
alpha-methyl-tyrosine (AMPT) and 3-iodo-L-tyrosine were
shown to be potent TH inhibitors [5,6,83]. Due to the rapid
degradation 3-iodo-L-tyrosine in vivo, it has not been sub-
jected to detailed pharmacological studies. However, AMPT
has been used in clinical trials in humans to treat hypertension
in patients with pheochromocytoma but has been less effec-
tive in the treatment of essential hypertension in humans
[59,84]. More recently, the tyrosine analog 3-fluoro-L-α-
methyl-tyrosine has also been shown to be effective in ima-
ging of malignant tumors, due to its high affinity to the L-type
amino acid transporter [85].
A range of synthetic analogs of the BH4 co-substrate has
also been synthesized and shown to support enzymatic activ-
ity for all the AAAHs [5,6,86,87]. As some of the BH4 analogs
containing hydrophobic substituents in 6-position of the pyr-
azine moiety have higher affinities for the AAAHs than the
natural cofactor 6R-BH4, they have been suggested to be
effective in stimulating monoamine production in vivo
[86,87]. However, due to their limited solubility and poor
blood–brain barrier penetration, the therapeutic value of
these compounds has so far been limited. The structural
basis for these interactions with TH, TPH1, TPH2, and PAH
has previously been reviewed [26].
In addition to compounds targeting the amino acid and
BH4 binding sites, iron chelators, and structural analogs of the
catecholamine feedback inhibitors have been tested as TH
inhibitors. As the natural catecholamines are nonspecific inhi-
bitors of the all the AAAHs, search for more potent and
selective catechol analogs has been conducted [34]. These
studies showed that dopamine agonists such as SKF-38393
and apomorphine are potent inhibitors of human TH and
possibly can contribute to the clinical effects of such com-
pounds [34]. Tetrahydroisoquinolines are catecholamine deri-
vatives formed in the nigrostriatal system of the human brain.
It has been reported that the levels of these compounds are
increased in the cerebrospinal fluid of patients with
Parkinson’s disease, but the clinical significance of this finding
is unclear. These catechol type of TH inhibitors include
N-methyl-norsalsolinol and salsolinol that are hypothesized
to contribute to the decreased production of catecholamines
found in Parkinson’s disease [88,89].
An early indication that the AAAHs were iron containing
enzymes came from the inhibitory effects of metal ion chelators
[31]. Several low-molecular chelators bind to the active site iron
and some of these also effectively extract the iron from the
enzyme [90]. Some of these inhibitory chelators also inhibit the
AAAHs in vivo and have been proposed as agents to explore
their physiological functions, although their therapeutic poten-
tial probably is limited, due to their lack of specificity [91].
3.3. TPH1 and TPH2 in human physiology, disease, and
mouse models of TPH1 and TPH2
The majority of peripheral serotonin, which is produced by
TPH1, is found in the intestine where it is involved in gastro-
intestinal motility and homeostasis [92]. Circulating serotonin
is mainly stored in platelet dense granules and is involved in
regulation of platelet aggregation [93] not only through
receptor binding but also by protein serotonylation that acti-
vate alpha-granule release [90]. Released serotonin increases
vasoconstriction and has been implicated in vascular remodel-
ing, leading to pulmonary arterial hypertension [72]. In addi-
tion, it has been suggested that inhibitors of TPH1 may be
used to treat or prevent thrombosis [94].
Further investigations of the Tph1-knockout mouse have
indicated a role of peripheral serotonin in bone density remo-
deling through stimulation of osteoclastogenesis, leading to
lowered bone density [95]. Pharmacologic inhibition of TPH1
confirms this observation [62]. Interestingly, Tph1-knockout
mice show protection from obesity and insulin resistance
from high-fat diet, suggesting a role for serotonin in brown
adipose tissue thermogenesis and identifying TPH1 as a pos-
sible target for treatment of obesity and metabolic dysfunc-
tion [70]. Carcinoid syndrome is a condition that is associated
with elevated peripheral serotonin, gastrointestinal symptoms,
and cardiac vascular disease [65]. Inhibition of TPH1 is an
approach to target some of the symptoms associated with
this syndrome.
In contrast to Th knockouts that are not viable, mice har-
boring the combined deletion of both Tph1 and Tph2 genes
are viable but display behavioral changes compatible with a
role of serotonin in brain function [96]. Tph2−/− mice have
impaired early postnatal growth as well as many physiological
differences, the most notable being an altered autonomic
sleep pattern. In addition, these mice have several behavioral
differences including decreased anxiety, increased aggression,
and maternal neglect [76,97].
In humans, several disorders have been reported to be
related to dysregulation of the serotonin system such as
depression, schizophrenia, and ADHD [98]. Serotonin dysregu-
lation has also been proposed to play a role in autism [99].
Variants in TPH2 have also been associated with major depres-
sion, bipolar disorder, suicidal behavior, personality disorder,
and ADHD [100]. However, in large genome wide association
studies, common variants in TH, TPH1, or TPH2 have not
shown convincing associations with any known human phe-
notypes tested so far. A recent comprehensive analysis of
variants in TH, TPH1, and TPH2, as well as the 14-3-3 genes
(YWHAs), across several psychiatric disorders has shown mod-
est effects for the hydroxylase genes, but significant associa-
tion of 14-3-3 epsilon (YWHAE) with schizophrenia [100].
As for TH, many rare coding variants, including complete
loss of function variants, have been described for TPH1 and
TPH2. Unlike for TH, humans homozygous for complete loss of
function variants of TPH1 and TPH2 have not been described.
However, many heterozygous missense variants are known
and have been reported to be associated with various psy-
chiatric phenotypes [101,102]. Intriguingly, maternal loss of
function variants in TPH1 are associated with increased






































psychiatric symptoms in the offspring, as also found in mouse
TPH1-knockout studies [103,104]. In addition, mutations in
TPH1 as a peripheral enzyme have been reported to be
involved in gastrointestinal disorders [32]. TPH1 inhibitors
and TPH1 knockouts have been shown to be effective in
treating pulmonary arterial hypertension in mouse models
[75] and have been suggested for treatment in humans
[72–75].
3.4. Synthetic TPH1 and TPH2 inhibitors and substrates
Since the AAAHs were discovered around 1960, research on
these enzymes has been conducted in parallel. The same
classes of synthetic substrates and inhibitors have been tested
for all enzymes, mainly targeting the amino acid binding site,
cofactor binding, and the active site iron, as mentioned for TH.
A number of patents have recently been filed for novel phar-
macological compounds to inhibit TPH and its use to treat
serotonin associated disorders [105–108].
The substrate analog p-chlorophenylalanine (fenclonine,
PCPA) has a modest affinity for these enzymes in vitro
(IC50 ≈ 250 µM) [69]. However, in vivo it is a potent and
irreversible inhibitor of TPH (and PAH) that increases phenyla-
lanine levels and rapidly depletes serotonin from the nervous
system [109]. In contrast, it has little effect on catecholamine
levels. This compound has been frequently used in animal
studies to deplete serotonin levels and in limited human
studies to treat symptoms of carcinoid syndrome. However,
due to unacceptable side effects, including depression, it has
been abandoned for this indication in humans [66]. Still, much
of what we know about the physiological roles of serotonin is
based on animal experiments with this compound during the
past 50 years.
The mechanism of action of p-chlorophenylalanine has been
debated. It has been suggested that the halogenated amino
acid is a suicide substrate that is covalently incorporated into
the protein structures of PAH and TPH, but not TH [110].
However, as low amounts of radiolabelled p--
chlorophenylalanine were recovered from immunoprecipitated
TPH enzyme, an alternative hypothesis has been proposed,
namely that a metabolic derivative of p-chlorophenylalanine is
responsible for the irreversible inhibition. Different levels of the
postulated converting enzyme might explain why p--
chlorophenylalanine is not equally effective in depleting sero-
tonin levels in all serotonin producing tissues [111].
More recently, several new more selective and reversible
inhibitors of TPH1 and TPH2 have been synthesized and tested
in different systems [69,112,113]. Due to their similar active
site structures, these compounds inhibit purified TPH1 and
TPH2 to a similar extent [69]. However, due to the different
tissue distribution of the enzymes and the low blood–brain
barrier permeability of some of these relatively bulky com-
pounds, they mainly inhibit TPH1 in vivo [69]. Such TPH1
inhibitors have shown promising effects in treatment of osteo-
porosis in animal models [62,63]; however, the effectiveness of
TPH1 inhibitors as treatment for osteoporosis has been
debated [114]. The TPH inhibitor telotristat–etiprate (LX-
1032) has been shown to provide symptomatic relief in
patients with carcinoid syndrome [65]. Inhibition of TPH1 of
the enterochromaffin cells of the gut has been shown to
decrease levels of serotonin in the periphery and increase
bone formation [62]. Peripherally acting inhibitors of TPH1
have also shown promising effects in animal models of ulcera-
tive colitis [71], irritable bowel disease [68], obesity [70], pul-
monary arterial hypertension [74], asthma [115], and lung
fibrosis [116].
4. Novel opportunities for targeting TH and TPH in
monoamine therapy
4.1. PCs
PCs are a relatively new concept in the development of
therapeutics. PCs are small molecular weight compounds
that bind selectively to unstable protein conformations and
stabilize their native state and/or aid the refolding of mis-
folded conformations, recovering (totally or partially) the
native structure and proper function and trafficking
[14,117]. Proof of principle has been obtained for PCs that
restore protein function in unstable and partly misfolded
mutants associated with a number of loss-of-function mis-
folding diseases, due to their rescue of the mutant proteins
from degradation by the cellular quality control system
[118]. Several PCs against lysosomal disorders are already
in clinical trials demonstrating a promising approach toward
small molecule-based therapies [119,120]. These therapeu-
tics may be classified as active site-specific PCs, and non-
active site PCs [121]. The initially described PCs rather
belonged to the first type, which were developed through
derivatization of natural ligands and agonists [117,121], lar-
gely based on the realization that supplementation with
cofactor and coenzymes increases the activity and stability
of numerous variant enzymes [122]. Indeed, a chaperone
response on mutant PAH seems to be an important mole-
cular mechanism behind BH4-responsive PKU [123]. Similarly,
BH4 treatment increases TH activity and protein levels in
treated mice [124]. On the other hand, it is increasingly
recognized that development of non-active site PCs, espe-
cially those that show allosteric activating function, is to be
preferred [121,125], since they may induce a more active,
stable conformation on the target enzyme even during cat-
alysis, without inhibiting the activity. For the AAAHs, it has
been shown that several compounds effectively preserve TH
activity by their weak binding to the catalytic iron through a
pyrimidine nitrogen atom [126]. Thus, for TH, and likely also
for the TPHs, therapeutic options including combinations of
different types of PCs might be preferential [126].
4.2. Targeting PPIs
PPIs represent a large group of potential therapeutic tar-
gets both inside and outside the cell. PPIs are central to
most biological processes and their dysregulation is there-
fore involved in many disorders [127]. The human interac-
tome is estimated to be >650,000 interactions [128] and
based on this, it can be argued that PPI modulation is one
of the areas in drug discovery that holds the most promise
for novel therapeutic interventions. PPIs can be targeted






































using both inhibitors and stimulators. However, in general,
PPI stabilization has been less successful than PPI inhibi-
tion [129]. Indeed, PPIs are more susceptible to disruption,
and potent inhibitors of PPI interactions have been devel-
oped, with a few of recent rationally discovered PPI dis-
ruptors reaching clinical trials [127]. Nevertheless, small
peptide analogs and small molecule stabilizers of relevant
PPIs are also being discovered, such as stabilizers of the
retromer which limits APP processing in hippocampal neu-
rons [130], or of specific oligomeric forms, such as the non-
aggregating tetrameric conformation of α-synuclein [131].
In the case of 14-3-3 proteins, both inhibitors and stabili-
zers have been discovered and both categories of compounds
interact within the main phosphate groove of 14-3-3 [132].
Proteins that bind to 14-3-3, including TH and TPH, interact
with 14-3-3 at the phosphopeptide binding site involving the
specific arginines and tyrosine residues (Figure 5). Direct tar-
geting of the phospho-Ser/Thr recognition site would be
expected to inhibit broadly among 14-3-3 target proteins,
but with higher potency toward low affinity binders.
Although 14-3-3 proteins interact with many different targets,
there are still several possibilities to improve selectivity, such
as to target surface regions outside the phospho-peptide
recognition site. Also, in a kinetics modeling study of 14-3-3
interactions, we found that sensitivity toward changes in affi-
nity, as well as changes in signaling, input differed among
target types [133].
4.2.1. Targeting the complexes of TH-pSer19 and TPH2-
pSer19 with 14-3-3 proteins
As presented above (Section 2.4.3), Ser19-dependent activa-
tion of both TH and TPH requires the binding to 14-3-3
proteins. Stabilization of this interaction might be a therapeu-
tic option. In the case of the 14-3-3 proteins, both inhibitors
(R18, PDB: 1A38 [50]; FOBISIN101, PDB: 3RDH [134]) and stabi-
lizers (fusicoccin, PDB: 5EXA [135]; epibestatin, PDB: 3M50
[136]) have been found [129,132]. However, to achieve speci-
ficity for the multipartner 14-3-3 proteins, which have hun-
dreds of partners, this becomes very challenging. Recently, a
semi-synthetic natural product derivative has been discovered
that specifically stabilizes the cancer-relevant interaction of
Gab2 phosphorylated at Thr391 with 14-3-3 (PDB ID: 5EXA)
[135]. Whereas several experimental and virtual screening
strategies, as well as derivatization of natural ligands, are
methods customary used for the identification of compound
hits that stabilize unstable protein targets and may be poten-
tial PCs [14], the discovery of PCs to stabilize PPI requires the
integration of a large number of biochemical and biophysical
techniques with access to structural information of the PPI
interface [130,131].
5. Expert opinion
Most drugs that are effective against human neuropsychiatric
disorders and some drugs used in cardiovascular diseases
target a few receptors, transporters, and enzymes, mainly
within the classical monoaminergic neurotransmitter systems.
However, these proteins constitute a small fraction of
potential targets within the ubiquitous and complex mono-
amine signaling systems.
In the past, amino acid analogs have been developed as
inhibitors of the key regulatory enzymes TH, TPH1, and TPH2.
Such inhibitors have been essential in dissecting the physio-
logical roles of serotonin and catecholamines. More recently,
access to genetically modified animal models and genomic
data from large patient cohorts have revealed that catechola-
mines and serotonin also are essential endocrine and para-
crine signaling molecules in a diverse range of physiological
conditions and disease states. In particular, TPH1 and TPH2
inhibitors have shown promising results in the treatment of
carcinoid syndrome, gastrointestinal dysfunction, and possibly
asthma, osteoporosis, and bone homeostasis. This has trig-
gered a new interest in developing more potent and selective
inhibitors.
Here, we have reviewed this historical development, with a
focus on recent structural and mechanistic insights into the
TH, TPH1, and TPH2 enzymes and how these data can be
exploited in the search for new therapeutic compounds.
We point to the following areas of research that should be
further developed:
(1) High-resolution 3D structures are available for all these
three enzymes, notably for the catalytic domain includ-
ing complexes with substrates and inhibitors. This has
paved the way for rational drug design, where in silico
docking and modeling can be combined with in vitro
screening and combinatorial chemistry to develop
more effective compounds.
(2) While amino acid analogs have been successfully used
as inhibitors of all these enzymes, the BH4, and iron-
binding sites, as well as allosteric ligand binding modes
should be further explored.
(3) A first generation of PCs has been discovered that can
partially restore the functions of misfolded TH, TPH1,
TPH2, and PAH due to missense mutations. These data
are encouraging and provide hope of developing new
therapies for protein misfolding diseases, including THD
syndromes.
(4) Genetically modified organisms with selective knockout
or knock-in of these enzymes, or other signaling com-
ponents, are valuable disease models and experimental
tools. In particular, knock-in mice harboring unstable
missense variants of these enzymes are useful to test
the effects of PCs in vivo.
(5) TH, TPH1, and TPH2 are regulated by an intricate com-
bination of site-specific phosphorylation and interac-
tions in protein complexes. In theory, modulation of
the phosphorylation of hydroxylases and their interac-
tion with 14-3-3 proteins provide novel opportunities
for monoamine targeting that should be investigated.
(6) Successful application of novel therapies will require
more structural information, as well as understanding
of the cellular kinetics of regulatory mechanisms. This
information, together with more quantitative experi-
mental data, could be implemented in mathematical
models of monoamine synthesis. Such predictive mod-
els could become valuable tools to better understand






































the regulation of monoamine synthesis, release, and
recycling to allow effective targeting strategies to be
tested and evaluated.
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